Fox Chase Cancer Center News

PHILADELPHIA (August 21, 2019) – Fox Chase Cancer Center announces the hiring of Stephanie Greco, MD, who will join the Department of Surgical Oncology on September 3, focusing on melanoma, sarcoma, and GI.

PHILADELPHIA (August 20, 2019) – The immunostimulatory monoclonal antibody elotuzumab, given in combination with lenalidomide and dexamethasone, is approved for the treatment of patients with relapsed or refractory multiple myeloma. The drug binds signaling lymphocytic activation molecule family member 7 (SLAMF7), a protein that is highly expressed on the surface of myeloma cells.

PHILADELPHIA (August 19, 2019) – Fox Chase Cancer Center will proudly participate in the Philadelphia Undy RunWalk to support the Colorectal Cancer Alliance and their mission to end colorectal cancer with national prevention, research, and patient support initiatives. Saturday, September 14, 2019, in Paine’s Park.

PHILADELPHIA (August 16, 2019) – Recently, Fox Chase Cancer Center researchers found a potential way to sensitize a new subset of patients with high-grade serous ovarian carcinoma to PARP inhibitors, a promising drug used in some cases of this disease. Disruption of HSP90 function can lead to death of ovarian cancer cell lines without known defects in DNA repair mechanisms, such as BRCA1/2 mutations, when used in combination with a PARP inhibitor.

PHILADELPHIA (August 16, 2019) – Natural killer cells, which have an innate capacity to identify and kill tumor cells or virus-infected cells in humans, are an important part of the body’s immune system. Key in distinguishing healthy cells from abnormal cells by natural killer cells is their expression of killer cell immunoglobulin-like receptors (KIRs).

PHILADELPHIA (August 19, 2019) – A new study by researchers at Fox Chase Cancer Center provides more evidence that colorectal cancers diagnosed in younger patients may be distinct from those diagnosed in older patients.

PHILADELPHIA (August 14, 2019) – Patients with head and neck cancer lived longer when their treatment was coordinated by a dedicated multidisciplinary tumor board, according to a new study by clinicians at Fox Chase Cancer Center at Temple University Hospital and the Departments of Radiation Oncology and Otolaryngology-Head and Neck Surgery at the Lewis Katz School of Medicine at Temple University.

PHILADELPHIA (August 14, 2019) – Two researchers at the Fox Chase Cancer Center have received a grant to study the cell-cell communication between pancreatic cancer cells and fibroblastic stromal calls. The recipients of the National Cancer Institute grant are Igor Astsaturov, MD, PhD, an associate professor in the Department of Hematology/Oncology, and Edna Cukierman, PhD, an associate professor with the Cancer Biology Research Department.